Neuromedin B receptor (NMB-R, BB1) antagonist (Ki values are 20.9 and > 10000 nM for NMB and gastrin-releasing peptide receptors respectively). Selectively blocks NMB-suppressed glucose intake in vivo. Also a potent urotensin-II receptor antagonist (pA2 = 7.5 - 7.7) and displays affinity for somatostatin and μ-opioid receptors.
